

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
BIOMED

和 鉑 醫 藥 控 股 有 限 公 司

**HBM Holdings Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02142)**

## **DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board of the Company will be held on Monday, 28 August 2023 for the purpose of considering and approving the interim results of the Group for the six months ended 30 June 2023 and transacting any other business.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 16 August 2023

*As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.*